J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in ...

New Hyde Park, N.Y.-based Northwell Health has opened a $5.3 million digestive health center in Uniondale, N.Y., according to a March 20 report from Long Island Business News. The new center is a part ...

The following is a summary of "Worsening disease severity as measured by I-SEE associates with decreased treatment response ...

Researchers conducted a large-scale online survey of clinicians in the Asia-Pacific region to investigate treatment policies for the gastric cancer-causing bacteria Helicobacter pylori.

Helicobacter pylori bacteria is considered to be the main cause of gastric cancer, with the infection rate particularly high ...

PR Newswire DENVER Recent clinical data demonstrate how HepQuant DuO test results may be used to inform endoscopy screening decisions, monitor disease progression ...

There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, ...

Findings were announced from a phase 3 trial evaluating guselkumab subcutaneous induction therapy in patients with moderately to severely active ulcerative colitis.

Twenty-two BE patients underwent endoscopic imaging with a multimodal scanning fiber endoscope (mmSFE). In this pilot study, 92% of neoplastic lesions could be imaged by comparison with pathology, ...

By the linage tracing animal model, this transdifferentiation is further confirmed by using α cell lineage-tracing. With the dapagliflozin therapy, some insulin-positive cells were located in the duct ...